179 related articles for article (PubMed ID: 36264430)
21. A randomized, observer-blind, vehicle-control, multi-center clinical investigation for assessing the efficacy and tolerability of a 1% ectoine and hyaluronic acid 0.1%-containing medical device in pediatric patients with mild-to-moderate atopic dermatitis.
Alexopoulos A; Dakoutrou M; Nasi L; Thanopoulou I; Kakourou T; Kontara L; Douladiris N; Galani M; Xepapadaki P; Doxani C; Mprotsis T; Zintzaras E; Papadopoulos NG; Kanaka-Gantenbein C; Chrousos GP
Pediatr Dermatol; 2023 Jan; 40(1):78-83. PubMed ID: 36038984
[TBL] [Abstract][Full Text] [Related]
22. Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States.
Varnado OJ; Ye W; Mi X; Burge R; Hall J
J Med Econ; 2023; 26(1):149-157. PubMed ID: 36601798
[TBL] [Abstract][Full Text] [Related]
23. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
Rosmarin D; Pandya AG; Lebwohl M; Grimes P; Hamzavi I; Gottlieb AB; Butler K; Kuo F; Sun K; Ji T; Howell MD; Harris JE
Lancet; 2020 Jul; 396(10244):110-120. PubMed ID: 32653055
[TBL] [Abstract][Full Text] [Related]
24. Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study.
Mihara R; Kabashima K; Furue M; Nakano M; Ruzicka T
J Dermatol; 2019 Aug; 46(8):662-671. PubMed ID: 31166620
[TBL] [Abstract][Full Text] [Related]
25. Ruxolitinib cream for the short-term treatment of mild-moderate atopic dermatitis.
Krajewski PK; Szepietowski JC
Expert Rev Clin Immunol; 2023 Apr; 19(4):349-356. PubMed ID: 36542765
[TBL] [Abstract][Full Text] [Related]
26. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
Worm M; Thyssen JP; Schliemann S; Bauer A; Shi VY; Ehst B; Tillmann S; Korn S; Resen K; Agner T
Br J Dermatol; 2022 Jul; 187(1):42-51. PubMed ID: 35084738
[TBL] [Abstract][Full Text] [Related]
27. Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year.
Hu W; Thornton M; Livingston RA
Am J Clin Dermatol; 2024 Mar; 25(2):327-332. PubMed ID: 38243107
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials.
Hebert A; Thiboutot D; Stein Gold L; Cartwright M; Gerloni M; Fragasso E; Mazzetti A
JAMA Dermatol; 2020 Jun; 156(6):621-630. PubMed ID: 32320027
[TBL] [Abstract][Full Text] [Related]
30. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
Front Immunol; 2020; 11():620098. PubMed ID: 33658996
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
32. Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives.
Eichenfield LF; Liu J; Marwaha S; Piercy J; Sturm D; Anderson P
Dermatol Ther (Heidelb); 2024 Mar; 14(3):685-696. PubMed ID: 38453811
[TBL] [Abstract][Full Text] [Related]
33. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
34. A randomized double-blind controlled trial to compare a triclosan-containing emollient with vehicle for the treatment of atopic dermatitis.
Tan WP; Suresh S; Tey HL; Chiam LY; Goon AT
Clin Exp Dermatol; 2010 Jun; 35(4):e109-12. PubMed ID: 19843084
[TBL] [Abstract][Full Text] [Related]
35. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis.
Peppers J; Paller AS; Maeda-Chubachi T; Wu S; Robbins K; Gallagher K; Kraus JE
J Am Acad Dermatol; 2019 Jan; 80(1):89-98.e3. PubMed ID: 30554600
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs.
Cao XC; Lu JW; Feng YF; Song LB; Lu Y
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4657-4662. PubMed ID: 38358466
[TBL] [Abstract][Full Text] [Related]
37. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
38. The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study.
Gooderham M; Kircik L; Zirwas M; Lee M; Kempers S; Draelos Z; Ferris L; Jones T; Saint-Cyr Proulx E; Bissonnette R; Bhatia N; Koppel R; Guenthner S; Eads K; Welgus H; Merritt C; Elias M; Navale L; Higham R; Droege M; Berk D
J Drugs Dermatol; 2023 Feb; 22(2):139-147. PubMed ID: 36745371
[TBL] [Abstract][Full Text] [Related]
39. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
40. Efficacy, safety, and treatment patterns of ruxolitinib 1.5% cream in adult atopic dermatitis: A single center retrospective study.
Stefanko NS; Quan VL; Chovatiya R
J Am Acad Dermatol; 2023 Aug; 89(2):415-417. PubMed ID: 37094652
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
